The Angiopoietin Related Protein 3 pipeline drugs market research report outlays comprehensive information on the Angiopoietin Related Protein 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Angiopoietin Related Protein 3 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Metabolic Disorders, Cardiovascular, Musculoskeletal Disorders, and Genito Urinary System which include the indications Hypertriglyceridemia, Homozygous Familial Hypercholesterolemia (HoFH), Atherosclerosis, Osteoarthritis, and Chronic Kidney Disease (Chronic Renal Failure). It also reviews key players involved in Angiopoietin Related Protein 3 targeted therapeutics development with respective active and dormant or discontinued products.

The Angiopoietin Related Protein 3 pipeline targets constitutes close to 17 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 5, 4, 1, 4, and 2 respectively.

Angiopoietin Related Protein 3 overview

Angiopoietin-like 3 (ANGPTL3) is a protein that function in angiogenesis. Expressed predominantly in the liver, it is further processed into an N-terminal coiled-coil domain-containing chain and a C-terminal fibrinogen chain. The N-terminal chain is important for lipid metabolism, while the C-terminal chain may be involved in angiogenesis.

For a complete picture of Angiopoietin Related Protein 3’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.